{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:32:43Z","timestamp":1790137963664,"version":"4.0.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Endocrinology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.mce.2020.111040","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T11:20:56Z","timestamp":1601551256000},"page":"111040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity"],"prefix":"10.1016","volume":"519","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1514-0244","authenticated-orcid":false,"given":"Alexsandra C.","family":"Malaquias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2567-7360","authenticated-orcid":false,"given":"Alexander A.L.","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mce.2020.111040_bib1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajhg.2013.05.021","article-title":"'Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS\/MAPK pathway syndrome","volume":"93","author":"Aoki","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/jhg.2015.114","article-title":"'Recent advances in RASopathies","volume":"61","author":"Aoki","year":"2016","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/ng1641","article-title":"'Germline mutations in HRAS proto-oncogene cause Costello syndrome","volume":"37","author":"Aoki","year":"2005","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/BF03401289","article-title":"'IGF-I generation test in prepubertal children with Noonan syndrome due to mutations in the PTPN11 gene","volume":"12","author":"Bertelloni","year":"2013","journal-title":"Hormones (Basel)"},{"key":"10.1016\/j.mce.2020.111040_bib5","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1210\/jc.2005-0995","article-title":"'PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome","volume":"90","author":"Binder","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2020.111040_bib6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000097552","article-title":"'Noonan syndrome: genetics and responsiveness to growth hormone therapy","volume":"67","author":"Binder","year":"2007","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.mce.2020.111040_bib7","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/ng2113","article-title":"'Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype","volume":"39","author":"Brems","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ceb.2018.06.007","article-title":"'RAS GTPase-dependent pathways in developmental diseases: old guys, new lads, and current challenges","volume":"55","author":"Bustelo","year":"2018","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.mce.2020.111040_bib9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajmg.a.35234","article-title":"'Noonan-like syndrome with loose anagen hair associated with growth hormone insensitivity and atypical neurological manifestations","volume":"158A","author":"Capalbo","year":"2012","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ajhg.2019.04.013","article-title":"'Activating mutations of RRAS2 are a rare cause of noonan syndrome'","volume":"104","author":"Capri","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1530\/EJE-15-0922","article-title":"'Growth patterns of patients with Noonan syndrome: correlation with age and genotype","volume":"174","author":"Cessans","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mce.2020.111040_bib12","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1172\/JCI43910","article-title":"'Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation","volume":"120","author":"Chen","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mce.2020.111040_bib13","doi-asserted-by":"crossref","first-page":"11473","DOI":"10.1073\/pnas.1324128111","article-title":"'Next-generation sequencing identifies rare variants associated with Noonan syndrome","volume":"111","author":"Chen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mce.2020.111040_bib14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000339677","article-title":"'Response to growth hormone therapy in children with Noonan syndrome: correlation with or without PTPN11 gene mutation","volume":"77","author":"Choi","year":"2012","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.mce.2020.111040_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng.497","article-title":"'A restricted spectrum of NRAS mutations causes Noonan syndrome","volume":"42","author":"Cirstea","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.425","article-title":"'Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair","volume":"41","author":"Cordeddu","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib17","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1210\/er.2010-0023","article-title":"'Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity","volume":"32","author":"David","year":"2011","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2020.111040_bib18","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1073\/pnas.1119803109","article-title":"'Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature","volume":"109","author":"De Rocca Serra-Nedelec","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mce.2020.111040_bib19","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1128\/MCB.00646-09","article-title":"'Functional effects of PTPN11 (SHP2) mutations causing LEOPARD syndrome on epidermal growth factor-induced phosphoinositide 3-kinase\/AKT\/glycogen synthase kinase 3 beta signaling","volume":"30","author":"Edouard","year":"2010","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.mce.2020.111040_bib20","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1210\/jc.2004-2559","article-title":"'PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome","volume":"90","author":"Ferreira","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2020.111040_bib21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1365-2265.2008.03234.x","article-title":"'Analysis of the PTPN11 gene in idiopathic short stature children and Noonan syndrome patients","volume":"69","author":"Ferreira","year":"2008","journal-title":"Clin. Endocrinol."},{"issue":"16","key":"10.1016\/j.mce.2020.111040_bib77","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1093\/hmg\/ddu148","article-title":"Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis","volume":"23","author":"Flex","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.mce.2020.111040_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajmg.a.30189","article-title":"'Costello syndrome with growth hormone deficiency and hypoglycemia: a new report and review of the endocrine associations","volume":"129A","author":"Gregersen","year":"2004","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib23","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/ajmg.a.37781","article-title":"'A novel rasopathy caused by recurrent de novo missense mutations in PPP1CB closely resembles Noonan syndrome with loose anagen hair","volume":"170","author":"Gripp","year":"2016","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib24","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/ajmg.a.31815","article-title":"'Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome","volume":"143A","author":"Gripp","year":"2007","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib25","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.91225","article-title":"'Elucidation of MRAS-mediated Noonan syndrome with cardiac hypertrophy","volume":"2","author":"Higgins","year":"2017","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.mce.2020.111040_bib26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1507\/endocrj.EJ19-0371","article-title":"\u2019Long-term efficacy and safety of two doses of Norditropin((R)) (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients","volume":"67","author":"Horikawa","year":"2020","journal-title":"Endocr. J."},{"key":"10.1016\/j.mce.2020.111040_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1023\/A:1020914026829","article-title":"'Fibroblast growth factor receptor 3 mutations in achondroplasia and related forms of dwarfism","volume":"3","author":"Horton","year":"2002","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.mce.2020.111040_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/pr.2015.254","article-title":"'Growth references for Japanese individuals with Noonan syndrome","volume":"79","author":"Isojima","year":"2016","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.mce.2020.111040_bib29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3345\/kjp.2018.06842","article-title":"'Comparison of effectiveness of growth hormone therapy according to disease-causing genes in children with Noonan syndrome","volume":"62","author":"Jo","year":"2019","journal-title":"Korean J. Pediatr."},{"key":"10.1016\/j.mce.2020.111040_bib30","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/gim.2017.249","article-title":"'Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants'","volume":"20","author":"Johnston","year":"2018","journal-title":"Genet. Med."},{"key":"10.1016\/j.mce.2020.111040_bib31","first-page":"185","article-title":"'Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS\/MAPK pathway","volume":"71","author":"Jorge","year":"2009","journal-title":"Horm. Res."},{"key":"10.1016\/j.mce.2020.111040_bib32","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1074\/jbc.273.4.2344","article-title":"'Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling","volume":"273","author":"Kim","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2020.111040_bib33","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.M513068200","article-title":"'PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects'","volume":"281","author":"Kontaridis","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mce.2020.111040_bib34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1210\/jc.2005-0983","article-title":"'Noonan syndrome: relationships between genotype, growth, and growth factors","volume":"91","author":"Limal","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.mce.2020.111040_bib35","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1002\/ajmg.a.35519","article-title":"'Growth standards of patients with Noonan and Noonan-like syndromes with mutations in the RAS\/MAPK pathway","volume":"158A","author":"Malaquias","year":"2012","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib36","first-page":"1","article-title":"Impact of growth hormone therapy on adult height in patients with PTPN11 mutations related to noonan syndrome","author":"Malaquias","year":"2019","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.mce.2020.111040_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ajhg.2010.06.015","article-title":"'Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype","volume":"87","author":"Martinelli","year":"2010","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib38","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/ajmg.a.36255","article-title":"'GH Therapy and first final height data in Noonan-like syndrome with loose anagen hair (Mazzanti syndrome)","volume":"161A","author":"Mazzanti","year":"2013","journal-title":"Am. J. Med. Genet."},{"issue":"3","key":"10.1016\/j.mce.2020.111040_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ajhg.2020.06.018","article-title":"\u2018Enhanced MAPK1 function causes a neurodevelopmental disorder within the RASopathy clinical spectrum\u2019","volume":"107","author":"Motta","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib40","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.tibs.2006.03.009","article-title":"'MAPK signal specificity: the right place at the right time","volume":"31","author":"Murphy","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.mce.2020.111040_bib41","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41436-018-0041-5","article-title":"'Noonan syndrome associated with growth hormone deficiency with biallelic LZTR1 variants","volume":"21","author":"Nakaguma","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.mce.2020.111040_bib42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ng1749","article-title":"'Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome","volume":"38","author":"Niihori","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib43","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1001\/archpedi.1968.02100020377005","article-title":"'Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease","volume":"116","author":"Noonan","year":"1968","journal-title":"Am. J. Dis. Child."},{"key":"10.1016\/j.mce.2020.111040_bib44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000369012","article-title":"'The efficacy and safety of growth hormone therapy in children with noonan syndrome: a review of the evidence","volume":"83","author":"Noonan","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.mce.2020.111040_bib45","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/ajmg.a.20502","article-title":"'Adult height in Noonan syndrome","volume":"123A","author":"Noonan","year":"2003","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/EJE-08-0413","article-title":"'Long-term GH treatment improves adult height in children with Noonan syndrome with and without mutations in protein tyrosine phosphatase, non-receptor-type 11","volume":"159","author":"Noordam","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.mce.2020.111040_bib47","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/ng2073","article-title":"'Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy","volume":"39","author":"Pandit","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/humu.23175","article-title":"'Structural, functional, and clinical characterization of a novel PTPN11 mutation cluster underlying noonan syndrome","volume":"38","author":"Pannone","year":"2017","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.mce.2020.111040_bib49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF00441408","article-title":"'Noonan syndrome: growth and clinical manifestations in 144 cases","volume":"148","author":"Ranke","year":"1988","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.mce.2020.111040_bib50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies'","volume":"14","author":"Rauen","year":"2013","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib51","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/ng2078","article-title":"'Germline gain-of-function mutations in RAF1 cause Noonan syndrome","volume":"39","author":"Razzaque","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"'Noonan syndrome","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.mce.2020.111040_bib53","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng1926","article-title":"'Germline gain-of-function mutations in SOS1 cause Noonan syndrome","volume":"39","author":"Roberts","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib54","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1126\/science.1124642","article-title":"'Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome","volume":"311","author":"Rodriguez-Viciana","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.mce.2020.111040_bib55","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1542\/peds.2009-3207","article-title":"Noonan syndrome: clinical features, diagnosis, and management guidelines","volume":"126","author":"Romano","year":"2010","journal-title":"Pediatrics"},{"key":"10.1016\/j.mce.2020.111040_bib56","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1002\/ajmg.a.35534","article-title":"'Normative growth charts for individuals with Costello syndrome","volume":"158A","author":"Sammon","year":"2012","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib57","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/ng1748","article-title":"'Germline KRAS mutations cause Noonan syndrome","volume":"38","author":"Schubbert","year":"2006","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib58","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/adc.81.1.28","article-title":"'Feeding difficulties and foregut dysmotility in Noonan's syndrome'","volume":"81","author":"Shah","year":"1999","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.mce.2020.111040_bib59","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.devcel.2010.03.009","article-title":"'Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis'","volume":"18","author":"Stewart","year":"2010","journal-title":"Dev. Cell"},{"key":"10.1016\/j.mce.2020.111040_bib60","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1210\/mend.14.9.0513","article-title":"'Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B","volume":"14","author":"Stofega","year":"2000","journal-title":"Mol. Endocrinol."},{"issue":"2","key":"10.1016\/j.mce.2020.111040_bib61","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/er.2018-00146","article-title":"\u2019Non-classical growth hormone insensitivity (GHI): characterization of mild abnormalities of GH action","volume":"40","author":"Storr","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2020.111040_bib62","doi-asserted-by":"crossref","first-page":"E4494","DOI":"10.1073\/pnas.1406107111","article-title":"'LEOPARD syndrome-associated SHP2 mutation confers leanness and protection from diet-induced obesity","volume":"111","author":"Tajan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mce.2020.111040_bib63","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ejmg.2015.08.005","article-title":"'SHP2 sails from physiology to pathology","volume":"58","author":"Tajan","year":"2015","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib64","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1210\/er.2017-00232","article-title":"The RASopathy family: consequences of germline activation of the RAS\/MAPK pathway","volume":"39","author":"Tajan","year":"2018","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.mce.2020.111040_bib65","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/hmg\/ddy133","article-title":"'Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth","volume":"27","author":"Tajan","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib66","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.beem.2010.09.002","article-title":"'Noonan syndrome and clinically related disorders","volume":"25","author":"Tartaglia","year":"2011","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.mce.2020.111040_bib67","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng772","article-title":"'Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib68","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ng1939","article-title":"'Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome","volume":"39","author":"Tartaglia","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib69","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ghir.2014.10.001","article-title":"'Growth hormone replacement therapy in Costello syndrome","volume":"24","author":"Triantafyllou","year":"2014","journal-title":"Growth Hormone IGF Res."},{"key":"10.1016\/j.mce.2020.111040_bib70","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0092-8674(90)90252-A","article-title":"'Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus","volume":"62","author":"Viskochil","year":"1990","journal-title":"Cell"},{"issue":"Suppl. 1","key":"10.1016\/j.mce.2020.111040_bib71","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000329138","article-title":"'Growth hormone receptor: structure function relationships","volume":"76","author":"Waters","year":"2011","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.mce.2020.111040_bib72","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ghir.2015.11.005","article-title":"'Atypical defects resulting in growth hormone insensitivity","volume":"28","author":"Wit","year":"2016","journal-title":"Growth Hormone IGF Res."},{"key":"10.1016\/j.mce.2020.111040_bib73","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1399-0004.1986.tb00587.x","article-title":"'Growth curves for height in Noonan syndrome","volume":"30","author":"Witt","year":"1986","journal-title":"Clin. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib74","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1172\/JCI44929","article-title":"'MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation","volume":"121","author":"Wu","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.mce.2020.111040_bib75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/jmedgenet-2015-103018","article-title":"'Rare variants in SOS2 and LZTR1 are associated with Noonan syndrome","volume":"52","author":"Yamamoto","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.mce.2020.111040_bib76","doi-asserted-by":"crossref","first-page":"10472","DOI":"10.1074\/jbc.M113.450023","article-title":"'Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations","volume":"288","author":"Yu","year":"2013","journal-title":"J. Biol. Chem."}],"container-title":["Molecular and Cellular Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720720303427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303720720303427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:12:00Z","timestamp":1759587120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303720720303427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":77,"alternative-id":["S0303720720303427"],"URL":"https:\/\/doi.org\/10.1016\/j.mce.2020.111040","relation":{},"ISSN":["0303-7207"],"issn-type":[{"value":"0303-7207","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation of the MAPK pathway (RASopathies) and partial growth hormone insensitivity","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mce.2020.111040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111040"}}